CEFALY Launches Research Registry for Pregnant Women’s Migraine Relief

CEFALY Introduces the Pregnancy Registry for Migraine Treatment

Medical device company CEFALY Technology has recently announced the introduction of the CEFALY Pregnancy Registry, a research initiative aimed at assessing the safety of external trigeminal nerve stimulation (eTNS) for migraine treatment during pregnancy.

The Challenge of Managing Migraines During Pregnancy

Migraine is a widespread neurological condition that predominantly affects women, particularly those of childbearing age. Approximately 39 million Americans suffer from migraines, with women representing a significant majority.

Unique Considerations for Pregnant Women

Managing migraines during pregnancy can be particularly challenging. Current treatments often lack comprehensive data on their safety for expecting mothers. Limited options discourage women from effectively managing their condition without compromising the health of their unborn baby. Many pregnant women are inclined to select non-pharmacological therapies, and non-invasive eTNS has emerged as a popular alternative. However, comprehensive research is necessary to establish its safety during this critical period.

Details of the CEFALY Pregnancy Registry

The CEFALY Pregnancy Registry is designed to recruit participants aged between 18 and 44 years who are pregnant with a single child and have experienced headaches or migraines either prior to or during their pregnancy. Enrolled participants will be asked to complete a series of online surveys at various stages during and after their pregnancy. Importantly, participation does not necessitate the use of the CEFALY device or any other external trigeminal nerve stimulator. To encourage participation, compensation will be provided upon completion of the registry activities.

Collaboration for Effective Data Collection

The registry will leverage the expertise of Greenlight Guru Clinical, a partner known for its proficiency in clinical trial data management for medical devices. Their involvement will ensure streamlined data collection and analysis throughout the research process.

CEO’s Statement on the Registry

Jen Trainor McDermott, CEO of CEFALY Technology, expressed the dire need for effective treatment alternatives, stating, "For far too long, women have struggled to find a safe and effective treatment option for migraine during pregnancy. Many believe they must suffer in silence. We hope to make life better for millions of moms-to-be by studying the safety of eTNS migraine therapy during pregnancy." This initiative signals a hopeful change for many women looking for relief.

All About the CEFALY Device

CEFALY Technology is widely recognized for its development of the CEFALY device, a non-invasive, FDA-cleared medical gadget that has demonstrated clinical effectiveness in reducing migraine frequency and alleviating pain. This innovative device is placed on the forehead and targets the trigeminal nerve, a key area associated with migraine pain.

Connecting Treatment with Technology

The Bluetooth-enabled CEFALY Connected model enhances patient interaction with the CeCe Migraine Management app, which allows users to monitor treatment sessions and log migraine occurrences conveniently. This technology empowers users to gain valuable insights into their migraine patterns and optimize their management strategies accordingly.

About CEFALY Technology

Headquartered in Belgium with operations in the United States, CEFALY Technology is dedicated to developing advanced electronic solutions for medical applications. The company's mission emphasizes delivering innovative technologies that empower individuals wrestling with migraines to better manage their condition and enhance their overall quality of life.

To learn more about their offerings and initiatives, visit their official website and engage with their diverse social media presence on platforms like Facebook, Twitter, LinkedIn, Instagram, and TikTok.

Frequently Asked Questions

What is the CEFALY Pregnancy Registry?

The CEFALY Pregnancy Registry is a research initiative that collects data regarding the safety of eTNS as a migraine treatment option for pregnant women.

Who can participate in the registry?

Women aged 18 to 44 who are pregnant and have experienced migraine or headaches are eligible to join the CEFALY Pregnancy Registry.

How will data be collected?

Data will be gathered through online surveys completed by participants throughout their pregnancy and after delivery.

Are participants required to use CEFALY devices?

No, participation does not require the use of a CEFALY or any other external nerve stimulator.

What is CEFALY Technology's goal with this registry?

CEFALY aims to provide pregnant women with research-backed treatment options for migraines while ensuring the safety of their well-being and that of their unborn child.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.